



**ADULT MEDICATION GUIDELINE**

**TENOFOVIR with EMTRICITABINE**

**Scope (Staff):** All WNHS Staff

**Scope (Area):** Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

**Quick Links**

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

**Restrictions**

[Formulary: Highly Restricted](#)

[HIGH RISK Medication](#) 

**Medication Class**

Drug Class

**Presentation**

**Tablet:** Tenofovir 300mg with Emtricitabine 200mg

**Storage**

Store at room temperature, below 30°C

**Dose**

**Post exposure prophylaxis (PEP)**

**Oral:**

ONE tablet daily

Starter pack is available in EC and SARC.

A 28 day course of PEP is recommended

**Post exposure prophylaxis (PEP) in minors >35kg**

**Oral:**

ONE tablet daily PLUS Raltegravir  
 Total 28 day course available in SARC

**Administration**

Where PEP is recommended, it should be prescribed and started as soon as possible after the exposure and within 72 hours

**Monitoring**

BMD and renal function

**Pregnancy**

**1<sup>st</sup> Trimester:** Monitoring required  
**2<sup>nd</sup> Trimester:** Monitoring required  
**3<sup>rd</sup> Trimester:** Monitoring required

Maternal use of emtricitabine or tenofovir during pregnancy has not been associated with an increased risk of congenital malformations following first trimester exposure. This combination should not be withheld during pregnancy if it is the medicine of choice

**Breastfeeding**

Due to the risk of postnatal HIV transmission, women with HIV should use a safe available alternative feeding method to breastfeeding.  
 Small amounts of tenofovir and emtricitabine are transferred into breastmilk which have not resulted in significant infant exposure

**Comments**

**Related Policies, Procedures & Guidelines**

External Legislation, Standards and Policy (list and hyperlink)  
[Post-Exposure Prophylaxis for HIV Australian national Guidelines](#)  
**HDWA Mandatory Policies:**  
[WA Public Health HIV/AIDS Notification](#)  
**WNHS Clinical Practice Guidelines:**  
[Antimicrobial Stewardship \(AMS\) policy](#)

[Antimicrobial Restriction Category List](#)

[Exposures to Blood and Body Fluids](#)

**WNHS Pharmaceutical and Medicines Management Guidelines:**

[Medication Administration Guidelines](#)

## References

Australian Medicines Handbook. Tenofovir. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 Jan 19]. Available from: <https://amhonline.amh.net.au/>

Therapeutic Guidelines. Postexposure prophylaxis against bloodborne viruses. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2022 [cited 2022 Jan 19]. Available from: <https://tgldcdp.tg.org.au>









[Post-Exposure Prophylaxis \(PEP\) ASHM](#)

The Royal Women's Hospital. Tenofovir. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2022 Jan 19]. Available from: <https://thewomenspbmg.org.au/>

The Royal Women's Hospital. Emtricitabine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2022 Jan 19]. Available from: <https://thewomenspbmg.org.au/>

Hale TW. Emtricitabine. In: Medications and Mothers' Milk [Internet]. New York: Springer Publishing Company; 2022 [cited 2022 Jan 19]. Available from: <http://www.medsmilk.com>

Hale TW. Tenofovir. In: Medications and Mothers' Milk [Internet]. New York: Springer Publishing Company; 2022 [cited 2022 Jan 19]. Available from: <http://www.medsmilk.com>

Keywords	HIV, truvada, tenofovir, emtricitabine, post exposure prophylaxis, PEP				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	31/07/2015	Last Reviewed:	19/01/2022	Review Date:	Jan 2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	01/03/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.            Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.